On August 12, 2009, FDA granted tentative approval for a generic fixed dose combination product containing efavirenz/emtricitabine/fenofovir disoproxil fumarate 600 mg/200 mg/300 mg manufactured by Matrix Laboratories Limited of Hyberdad, India.
The details can be read here.
No comments:
Post a Comment